Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration

NCT06375239 is registered in ClinicalTrials.gov with Ray Therapeutics, Inc. as lead sponsor.

NCT NCT06375239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06375239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration
Lead sponsor
Ray Therapeutics, Inc.
Phase
Observational
Overall status
Recruiting
Start date
April 5, 2024
Completion date
April 30, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroideremia, geographic atrophy from age-related macular degeneration, retinal dystrophies, retinitis pigmentosa, stargardt disease, stargardt macular dystrophy, x-lined retinoschisis